Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium

About this update from Tempus Ai, Inc.

[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nTempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS). The meeting takes place December 9–12 at the Henry B. González Convention Center in San Antonio, Texas.\n\n“This year at SABCS, our research highlights the power of multimodal data to help unravel the complexity of breast cancer,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “By integrating genomic, transcriptomic, and real-world clinical data, we are moving beyond broad disease classifications to uncover specific molecular drivers of progression and resistance. These insights are essential for pinpointing patient populations who may benefit from novel therapies and for optimizing treatment strategies to ultimately improve outcomes for those with advanced disease.”\n\nTempus will highlight its latest scientific and clinical research findings via ten poster presentations:\n\n\nIntegrative Modeling of Multimodal Real-World Data for Improved Risk Stratification of First-Line CDK4/6 Inhibitor Outcomes in Patients with Estrogen Receptor (ER)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer\n\n\nDate/Time: Wednesday, December 10, 2025, 12:30 p.m. - 2:30 p.m. CDT\n\n\nPresentation Number: PS1-11-08\n\n\nSummary: We developed a machine learning model that used clinical, genomic, and transcriptomic features to stratify patients with ER-positive/HER2-negative metastatic breast cancer, based on response to first-line CDK4/6 inhibitor plus endocrine treatment and identify predictors of response. This study demonstrated that multimodal real-world data collected during routine care can provide valuable insights into the biology of response to CDK4/6 inhibitors in patients with metastatic breast cancer and help improve patient stratification.\n\n\n\n\nDistinct Transcriptional and Immunosuppressive Microenvironment Signatures in PIK3CA- and ESR1-Mutant Hormone Receptor Positive (HR+)/HER2- Metastatic Breast Cancer (MBC)\n\n\nDate/Time: Wednesday, December 10, 2025, 12:30 p.m. - 2:30 p.m. CDT\n\n\nPresentation Number: PS1-11-22\n\n\nSummary: This study compared transcriptomic and immune profiles in HR+/HER2- metastatic br...

More updates from Tempus Ai, Inc.